@article {1901, title = {A protocol to inject ocular drug implants into mouse eyes.}, journal = {STAR Protoc}, volume = {3}, year = {2022}, month = {2022 03 18}, pages = {101143}, abstract = {

Ocular drug implants (ODIs) are beneficial for treating ocular diseases. However, the lack of a robust injection approach for small-eyed model organisms has been a major technical limitation in developing ODIs. Here, we present a cost-effective, minimally invasive protocol to deliver ODIs into the mouse vitreous called Mouse Implant Intravitreal Injection (MI3). MI3 provides two alternative surgical approaches (air-pressure or plunger) to deliver micro-scaled ODIs into milli-scaled eyes, and expands the preclinical platforms to determine ODIs\&$\#$39; efficacy, toxicity, and pharmacokinetics. For complete details on the use and execution of this protocol, please refer to Sun et\ al. (2021).

}, keywords = {Animals, Drug Implants, Intravitreal Injections, Mice, Vitreous Body}, issn = {2666-1667}, doi = {10.1016/j.xpro.2022.101143}, author = {Lin, Cheng-Hui and Sun, Young Joo and Lee, Soo Hyeon and Mujica, Elena M and Kunchur, Caitlin R and Wu, Man-Ru and Yang, Jing and Jung, Youn Soo and Chiang, Bryce and Wang, Sui and Mahajan, Vinit B} } @article {645, title = {COMBINED VITRECTOMY AND INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT.}, journal = {Retina}, volume = {36}, year = {2016}, month = {2016 Nov}, pages = {2087-2092}, abstract = {

PURPOSE: To evaluate the safety and efficacy of combining intravitreal dexamethasone implantation (Ozurdex) with pars plana vitrectomy (PPV).

METHODS: A retrospective review was conducted on cases where Ozurdex injection was performed in the operating room in conjunction with pars plana vitrectomy. Our primary outcome measure was the presence of surgical complications in the perioperative and 3-month postoperative window. We also measured visual acuity, intraocular pressure (IOP), and macular edema at baseline, one, and 3 months after surgery.

RESULTS: Fifteen eyes in 14 cases were reviewed. There were no complications intraoperatively or at 1-month postoperatively. Two patients (2 eyes) with prior retinal detachment developed proliferative vitreoretinopathy and redetachment at 3 months. Visual acuity improved in 7 of 15 eyes, and an average improvement of 2 lines was achieved for the entire cohort. There was no overall change in intraocular pressure although 1 patient developed an increase in intraocular pressure \>5 mmHg. Five of 9 patients with baseline macular edema experienced improvement or resolution at 3 months.

CONCLUSION: Intraoperative Ozurdex in combination with PPV may be safe and effective in treating macular edema caused by many different underlying diseases.

}, keywords = {Adult, Aged, Aged, 80 and over, Combined Modality Therapy, Dexamethasone, Drug Implants, Female, Glucocorticoids, Humans, Intraocular Pressure, Intravitreal Injections, Macular Edema, Male, Middle Aged, Retinal Vein Occlusion, Retrospective Studies, Tomography, Optical Coherence, Uveitis, Posterior, Visual Acuity, Vitrectomy, Wet Macular Degeneration}, issn = {1539-2864}, doi = {10.1097/IAE.0000000000001063}, author = {Zheng, Andrew and Chin, Eric K and Almeida, David R P and Tsang, Stephen H and Mahajan, Vinit B} } @article {711, title = {Spontaneous dislocation of a fluocinolone acetonide implant (Retisert) into the anterior chamber and its successful extraction in sympathetic ophthalmia.}, journal = {Retin Cases Brief Rep}, volume = {9}, year = {2015}, month = {2015 Spring}, pages = {142-4}, abstract = {

PURPOSE: To report a case of spontaneous fluocinolone acetonide (Retisert) implant dislocation and migration into the anterior chamber.

METHODS: Retrospective case report.

PATIENTS: One patient with sympathetic ophthalmia uveitis was well controlled by fluocinolone acetonide implants.

RESULTS: The fluocinolone acetonide implant spontaneously migrated into the anterior chamber causing corneal edema and anterior chamber reaction. The implant was subsequently successfully removed through a temporal corneal wound.

CONCLUSION: Clinicians should be aware of the spontaneous dislocation and migration of an intact fluocinolone implant as a potential surgical complication, particularly in pseudophakic eyes with iridectomy.

}, keywords = {Anterior Chamber, Device Removal, Drug Implants, Fluocinolone Acetonide, Glucocorticoids, Humans, Male, Middle Aged, Ophthalmia, Sympathetic, Visual Acuity}, issn = {1937-1578}, doi = {10.1097/ICB.0000000000000119}, author = {Almeida, David R P and Chin, Eric K and Mears, Katrina and Russell, Stephen R and Mahajan, Vinit B} } @article {171, title = {Management of sympathetic ophthalmia with the fluocinolone acetonide implant.}, journal = {Ophthalmology}, volume = {116}, year = {2009}, month = {2009 Mar}, pages = {552-557.e1}, abstract = {

We examined whether implantation of the fluocinolone acetonide (Retisert) implant achieved control of inflammation and a reduced need for oral corticosteroids or immunosuppressives in patients with sympathetic ophthalmia (SO).

}, keywords = {Adult, Aged, Drug Implants, Female, Fluocinolone Acetonide, Follow-Up Studies, Glucocorticoids, Humans, Immunosuppressive Agents, Intraocular Pressure, Male, Middle Aged, Ophthalmia, Sympathetic, Retrospective Studies, Treatment Outcome, Visual Acuity}, author = {Mahajan, Vinit B and Gehrs, Karen M and Goldstein, Debra A and Fischer, David H and Lopez, Juan S and Folk, James C} }